Summary
The extracellular matrix glycoprotein tenascin-C (TN) is overexpressed in the stroma of malignant ovarian tumours particularly at the interface between epithelia and stroma leading to suggestions that it may be involved in the process of invasion (Wilson et al (1996) Br J Cancer : 999–1004). To define regulation of TN further and investigate its function in ovarian cancer, a range of cell line models were studied. Concentrations of secreted TN in media from cultures of ovarian fibroblast cell lines were at least 100-fold greater than from carcinoma cell lines. Evidence for paracrine regulation of TN secretion was obtained by co-culture of carcinoma cells with fibroblast cells wherein secretion into the media was greater than from fibroblasts alone. Transforming growth factor (TGF)-β1, insulin-like growth factor (IGF)-II and progesterone all stimulated TN secretion while human choriogonadotropin (hCG), follicle-stimulating hormone (FSH) and γ-interferon inhibited secretion. TGF-β1 produced the greatest stimulation of TN in cultured fibroblasts and its co-expression with TN was examined in primary ovarian tumours. There was a significant association between the presence of moderate–strong expression of TN and TGF-β1. Evidence for TN having a functional role in ovarian carcinoma was obtained from adhesion and migration assays. The PE01, PE04, SKOV-3 and 59M cell lines all demonstrated marked adhesion to plastic coated with TN relative to the control protein bovine serum albumin (BSA) and expressed α2β1 and α3β1 integrins. The SKOV-3 cell line migrated more rapidly through TN than through BSA indicating that TN can facilitate migration of ovarian carcinoma cells.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bartlett, J. M. S., Langdon, S. P., Scott, W. N., Love, S. B., Miller, E. P., Katsaros, D., Smyth, J. F. & Miller, W. R. (1997). Transforming growth factor beta isoform expression in human ovarian tumors. Eur J Cancer 33: 2397–2403.
Brunner, K. T., Enger, H. D. F. & Cerottini, J. C. (1976). The 51Cr release assay as used for the quantitative measurement of cell mediated cytolysis in vivo. In Vitro Methods in Cell-Mediated and Tumour Immunity. Bloom BR and Davids JHR (eds), pp. 423–436. Academic Press: New York
Chiquet-Ehrismann, R. (1993). Tenascin and other adhesion-modulating proteins in cancer. Semin Cancer Biol 4: 301–310.
Chiquet-Ehrismann, R., Kalla, P., Pearson, C., Beck, K. & Chiquet, M. (1988). Tenascin interferes with fibronectin action. Cell 53: 383–390.
Chiquet-Ehrismann, R., Kalla, P. & Pearson, C. A. (1989). Participation of tenascin and transforming growth factor-β in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Res 49: 4322–4325.
Chung, C. Y. & Erickson, H. P. (1994). Cell surface annexin-II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J Cell Biol 126: 539–548.
Deryugina, E. I. & Bourdon, M. A. (1996). Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci 109: 643–652.
Erickson, H. & Bourdon, M. (1989). Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumours. Ann Rev Cell Biol 5: 71–92.
Giese, A., Loo, M. A., Norman, S. A., Treasurywala, S. & Berens, M. E. (1996). Contrasting migratory response of astrocytoma cells to tenascin mediated by different integrins. J Cell Sci 109: 2161–2168.
Hoffman, S., Dutton, S. L., Ernst, H., Boakle, M. K., Everman, D., Tourkin, A. & Loike, J. D. (1994). Functional characterisation of antiadhesion molecules. Perspect Dev Neurobiol 2: 101–110.
Langdon, S. P., Lawrie, S. S., Hay, F. G., Hawkes, M. M., McDonald, A., Hayward, I. P., Schol, D. J., Leonard, R. C. F. & Smyth, J. F. (1988). Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 48: 6166–6172.
Mackie, E. J., Chiquet-Ehrismann, R., Pearson, C. A., Inaguma, Y., Taya, K., Kawarada, Y. & Sakakura, T. (1987). Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci USA 84: 4621–4625.
Mould, A. L., Askari, J. A., Craig, S. E., Garratt, A. N., Clements, J. & Humphries, M. J. (1994). Integrin α4β1-mediated melanoma cell adhesion and migration on vascular adhesion molecule-1 (VCAM-1) and the alternatively spliced IIICS region of fibronectin. J Biol Chem 269: 27224–27230.
Pearson, C. A., Pearson, D., Shibahara, S., Hofsteenge, J. & Chiquet-Ehrismann, R. (1988). Tenascin: cDNA cloning and induction by TGF-β. EMBO J 7: 2977–2981.
Rettig, W. J., Erickson, H. P., Albino, A. P. & Garin-Chesa, P. (1994). Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways. J Cell Sci 107: 487–497.
Spring, J., Beck, K. & Chiquet-Ehrismann, R. (1989). Two contrary functions of tenascin: dissection of the active site by recombinant tenascin fragments. Cell 59: 325–334.
Walker, R. A., Daring, S. J. & Gallacher, B. (1994). Relationship of transforming growth factor β1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br J Cancer 69: 1160–1165.
Wilson, K. E., Langdon, S. P., Lessells, A. M. & Miller, W. R. (1996). Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. Br J Cancer 74: 999–1004.
Yokasaki, Y. & Sheppard, D. (1995). Integrin receptors for extracellular matrix with special reference to tenascin. Trends Glycosci Glycotechnol 7: 417–427.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Wilson, K., Bartlett, J., Miller, E. et al. Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines. Br J Cancer 80, 685–692 (1999). https://doi.org/10.1038/sj.bjc.6690410
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690410
Keywords
This article is cited by
-
Diabetes and ovarian cancer: risk factors, molecular mechanisms and impact on prognosis
Endocrine (2023)
-
Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing
Journal of Ovarian Research (2018)
-
Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis
British Journal of Cancer (2017)
-
Clinical significance of serum tenascin-c levels in epithelial ovarian cancer
Tumor Biology (2014)
-
Tenascin-C is expressed by human glioma in vivo and shows a strong association with tumor blood vessels
Cell and Tissue Research (2013)